Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company, specializes in the emerging field of molecular medicine. The company is committed to applying innovations in the identification and targeting of disease to enhance patient healthcare by treating significant, but unmet medical needs. Their focus is on discovering, developing and commercializing novel radiotherapeutics and molecular imaging pharmaceuticals for initial application in the areas of oncology and cardiology. For further information, visit the Company’s web site at www.molecularinsight.com.
- 18 years ago
QualityStocks
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…